CAMP4 Therapeutics Corporation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CAMP4 Therapeutics Corporation (CAMP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $379.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- CAMP4 Therapeutics Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- CAMP4 Therapeutics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.40M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $379.00K 10-Q · filed 2026-08-13 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.40M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |